Hennion & Walsh Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.57M | Buy |
70,637
+9,477
| +15% | +$345K | 0.1% | 257 |
|
|
2025
Q1 | $2.21M | Sell |
61,160
-2,060
| -3% | -$74.6K | 0.1% | 250 |
|
|
2024
Q4 | $2.66M | Sell |
63,220
-14,875
| -19% | -$626K | 0.12% | 215 |
|
|
2024
Q3 | $4.34M | Buy |
78,095
+4,806
| +7% | +$267K | 0.2% | 119 |
|
|
2024
Q2 | $3.01M | Buy |
73,289
+23,752
| +48% | +$976K | 0.15% | 166 |
|
|
2024
Q1 | $2.31M | Buy |
49,537
+14,159
| +40% | +$661K | 0.12% | 227 |
|
|
2023
Q4 | $1.69M | Buy |
35,378
+15,627
| +79% | +$747K | 0.1% | 274 |
|
|
2023
Q3 | $704K | Buy |
19,751
+1,426
| +8% | +$50.8K | 0.04% | 435 |
|
|
2023
Q2 | $845K | Buy |
18,325
+363
| +2% | +$16.7K | 0.05% | 403 |
|
|
2023
Q1 | $720K | Buy |
17,962
+3,048
| +20% | +$122K | 0.04% | 430 |
|
|
2022
Q4 | $691K | Buy |
+14,914
| New | +$691K | 0.04% | 418 |
|